Mural Oncology Advances Drug Pipeline and Extends Runway

Mural Oncology Plc ( (MURA) ) just unveiled an announcement.

Mural Oncology announced significant progress in its drug development pipeline, highlighting upcoming data readouts for its investigational therapy, nemvaleukin, in 2025. The company has extended its cash runway into Q1 2026 through operational efficiencies and plans to nominate new candidates and submit an IND for a phase 1 trial of MURA-8518 by Q4 2025. These developments position Mural Oncology as a key player in addressing unmet needs in cancer treatment, potentially benefiting patients and stakeholders with innovative therapies.

More about Mural Oncology Plc

Mural Oncology is a clinical-stage immuno-oncology company that focuses on developing cytokine-based immunotherapies for cancer treatment. Leveraging its protein engineering platform, Mural’s lead candidate, nemvaleukin, targets IL-2 pathways and is in late-stage trials for platinum-resistant ovarian cancer and mucosal melanoma.

YTD Price Performance: 14.06%

Average Trading Volume: 166,051

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $62.27M

For an in-depth examination of MURA stock, go to TipRanks’ Stock Analysis page.